New York (HedgeCo.Net) – One of Forbes’ magazine’s “30 Under 30” finance wizards has donated $1 million to Hunter College High School, the largest single gift in the high school’s 101-year history.
Currently a health care investor and entrepreneur, Martin Shkreli, was a student at HCHS from 1994-2000. He graduated from Baruch College in 2004 and then launched a stand-out career on Wall Street, with stints at several major hedge funds, including Cramer, Berkowitz & Co. and Intrepid Capital Management. In 2009, he established his own firm, MSMB, which made a number of highly successful trades focused on short-selling strategies.
“I owe so much of my success over the past 15 years to my time as a Hunter student.”
Shkreli said, “Beyond its great teachers and academics, Hunter encouraged me to think creatively and to challenge conventional wisdom. Hunter is a wonderful educational incubator and I’m hoping the endowment set up in my name will help train a new generation of students to stay ahead of the curve and also motivate them to always see around the corner.”
The Shkreli gift, to be managed by a new endowment fund in his name, is earmarked for a variety of uses, including funding new technology and teaching resources for the school’s science and guidance programs. The endowment also aims to generally assist Hunter in “supporting and expanding its reputation as one of the premier schools in New York City and the United States.”
Among the nation’s top secondary schools, HCHS is uniquely governed, the only New York City public high school not under control of New York City’s Department of Education.
“As Hunter’s President and a graduate of Hunter College High School myself, I know the critical difference a major gift like this can make in bringing positive change to campus,” said Hunter College President Jennifer J. Raab. “We thank Martin Shkreli for his vision and his dedication to HCHS, and know that his generosity will only make a great school even better.”
In 2011, he formed Retrophin, a biotech company that had its successful IPO in 2013 on the NASDAQ exchange. Shkreli left Retrophin in 2014 and last week launched a new life sciences company, Turing Pharmaceuticals, which is currently developing a portfolio of new drug treatments for major medical conditions. A serious student of biochemistry and pharmacology, Shkreli holds several drug patents under his own name.
Alex Akesson
Editor for HedgeCo.net
alex@hedgeco.net
HedgeCo.Net is a premier hedge fund database and community for qualified and accredited investors only. Membership in HedgeCo.net is FREE and EASY. We also offer FREE LISTINGS for Hedge Funds!
